Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study^*

References

• Lunning MA, Moskowitz AJ, Horwitz S. Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve. J Clin Oncol. 2013;31:1922–1927.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edn. Lyon: IARC; 2008.
   Google Scholar
• Savage K, Chhanabhai M, Gascoyne R, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15:1467–1475.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–1006.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. 2017. T-Cell Lymphomas Version 1.2017. [Internet].
   Google Scholar
• Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116:3418–3425.
   PubMed Web of Science ®Google Scholar
• Vose JM, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–4130.
   PubMed Web of Science ®Google Scholar
• Ellin F, Landström J, Jerkeman M, et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2015;124:1570–1578.
   Web of Science ®Google Scholar
• Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the parma trial. JCO. 1998;16:3264–3269.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbreek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• El-Asmar J, Reljic T, Ayala E, et al. Efficacy of high-dose therapy and autologous hematopoietic cell transplantation in peripheral T-cell lymphomas as front-line consolidation or in the relapsed/refractory setting: a systematic review/meta-analysis. Biol Blood Marrow Transplant. 2015;22:802–814.
   PubMed Web of Science ®Google Scholar
• Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970–1976.
   PubMed Web of Science ®Google Scholar
• Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32:3490–3496.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244–1253.
   PubMed Web of Science ®Google Scholar
• Crump M, Kuruvilla JG, Kouroukis CT, et al. A randomized trial of rituximab vs observation following autologous stem cell transplantation (ASCT) for relapsed or refractory CD20-positive B cell lymphoma: final results of NCIC CTG LY. Blood. 2013;122:(suppl):155.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin’s lymphoma: the International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Armitage P, Berry G. Statistical methods in medical research. Oxford; Boston: Blackwell scientific; 1987.
   Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170.
   PubMedGoogle Scholar
• Cheung MC, Hay AE, Crump M, et al. Gemcitabine/Ddexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12. J Natl Cancer Inst. 2015;107:djv106. doi: 10.1093/jnci/djv106
   Google Scholar
• Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–2479.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Magagnoli M, Bendandi M, et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol. 1998;9:1351–1353.
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol. 2001;113:185–187.
   PubMed Web of Science ®Google Scholar
• Kogure Y, Yoshimi A, Ueda K, et al. Modified ESHAP regimen for relapsed/refractory T-cell lymphoma: a retrospective analysis. Ann Hematol. 2015;94:989–994.
   PubMed Web of Science ®Google Scholar
• Park B-B, Kim WS, Suh C, et al. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol. 2015;94:1845–1851.
   PubMed Web of Science ®Google Scholar
• Zelenetz A, Hamlin P, Kewalramani T, et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14:(suppl): i5–i10.
   PubMed Web of Science ®Google Scholar
• Nademanee A, Palmer J, Popplewell L, et al. High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors. Biol blood Marrow Transplant. 2013;17:1481–1489.
   Web of Science ®Google Scholar
• Smith SM, Burns LJ, Inwards DJ, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31:3100–3109.
   PubMed Web of Science ®Google Scholar
• Rodríguez J, Caballero MD, Gutiérrez A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14:1768–1775.
   PubMed Web of Science ®Google Scholar
• Vose JM, Peterson C, Bierman PJ, et al. Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas. Blood. 1990;76:424–431.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol. 1990;1:45–50.
   PubMed Web of Science ®Google Scholar
• Shimoyama M, Oyama A, Tajima K, et al. Differences in clinicopathological characteristics and major prognostic factors between B-lymphoma and peripheral T-lymphoma excluding adult T-cell leukemia/lymphoma [Internet]. Leuk Lymphoma. 1993;10:335–342.
   PubMed Web of Science ®Google Scholar
• Puig N, Wang L, Seshadri T, et al. Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;8194:1–7.
   Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1994;12:2543–2551.
   PubMed Web of Science ®Google Scholar
• Song KW, Mollee P, Keating A, et al. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol. 2003;120:978–985.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-García G, García-Herrera A, Cardesa T, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol. 2011;22:397–404.
   PubMed Web of Science ®Google Scholar
• Wang R, Lagakos SW, Ware JH, et al. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189–2194.
   PubMed Web of Science ®Google Scholar